莫西沙星治疗下呼吸道感染的临床研究

Moxifloxacin in Treatment of Lower Respiratory Tract Infection:Clinical Trials

目的评价莫西沙星治疗下呼吸道感染的临床疗效与安全性。方法评价病例99例，随机分为试验组50例，对照组49例，试验组静脉滴注莫西沙星注射剂400mg；1次／d，对照组静脉滴注左氧氟沙星注射剂400mg，1次／d，疗程均为7～14d。结果试验组和对照组的临床有效率分别为94．0％和79．6％，细菌清除率分别为94．3％和77．8％，两组临床有效率及细菌清除率比较差异均有统计学意义（P〈O．05）；试验组和对照组不良反应发生率分别为6．0％和8．2％，两组比较差异无统计学意义（P〉O．05）。结论莫西沙星注射剂治疗下呼吸道感染疗效确切，安全性好，有较高的临床应用价值。

OBJECTIVE To evaluate the efficacy and safety of moxifloxacin in treating lower respiratory infection. METHODS Totally 102 patients were enrolled in this study, but 3 cases were infixed or weeded. Fifty cases of trial group were given 400mg of moxifloxacin intravenously, once a day for 7-14 days, 49 cases of control group were given 400rag of levofloxacin intravenously, once a day for 7-14 days. RESULTS The clinical efficacious rates of moxifloxacin and levofloxacin were 94.0% and 79.6%, respectively. The bacterial clearance rates of moxifloxacin and levofloxacin were 94.3% and 77.8%, respectively. There was significant difference （P〈0.05） between two groups in the clinical efficacious rate and the bacterial clearance rate. The incidence of adverse drug reaction of moxifloxacin was 6.0% and of levofloxacin was 8. 2%, There was no significant difference （P〉0.05） between two groups. CONCLUSIONS Moxifloxacin injection is an effective and safe antibiotics for the treatment of lower respiratory tract infection.